Rondecabtagene autoleucel

Cell therapy

Phase 3underway

Evidence outlook · registrational

Large B-Cell Lymphoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-12.

Company guidance: topline data expected mid-2027 (NCT05826535; Lyell Immunopharma, Inc., 6 Aug 2026). “Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Large B-Cell Lymphoma
Phase 1/2 (1)
Large B-Cell Lymphoma

Competitive landscape

This drug's own stage for Large B-Cell Lymphoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rondecabtagene Autoleucel: this drugPhase 3Cell therapyCD19 / CD20not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinApprovedAntibody–drug conjugateAnti-CD30 antibody-drug conjugatenot yet gradedNo reviewed efficacy summary in this indication
EpcoritamabApprovedMultispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
TafasitamabApprovedMonoclonal antibodyCD19Weak signal
NCT02399085: Number of Participants With Best Objective Response Rate (ORR) (Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled): Treatment (MOR00208, Lenalidomide) — Approximately 4.5 years after first participant enrolled: 46 Participants; Approximately 6.5 years after first participant enrolled: 46 Participants
GolcadomidePhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 3Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene AnsegedleucelPhase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rondecabtagene autoleucel to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1/2Large B-Cell LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT05826535 · CT.gov ↗

Company guidance: topline data expected mid-2027 (Lyell Immunopharma, Inc., 6 Aug 2026). “Additional data from this trial are expected in the second half of 2026, and pivotal data are expected in mid-2027” Source ↗

What to watch
2029 (1)
December 2029 (1)
Phase 3Large B-Cell LymphomaRecruiting
Est. primary completion 2029-12 · NCT07188558 · CT.gov ↗
What to watch

See the full readout calendar ↗